Rates of Thy 1‐non‐diagnostic thyroid fine needle aspiration using the UK Royal College of Pathologists Thy Terminology. A systematic review of the literature comparing patients who undergo rapid on‐site evaluation and those who do not

Introduction The UK Royal College of Pathologists (RCPath) Thy terminology is an internationally recognised system for reporting thyroid fine needle aspiration. The terminology has been used throughout the UK and Ireland, in some parts of Italy and Switzerland, and elsewhere in the world. There is n...

Full description

Saved in:
Bibliographic Details
Published in:Cytopathology (Oxford) 2020-11, Vol.31 (6), p.502-508
Main Authors: Poller, David N., Doyle, Victoria, Trimboli, Pierpaolo, Bongiovanni, Massimo
Format: Article
Language:English
Subjects:
cytology
Diagnosis
inadequate
Literature reviews
rapid on‐site evaluation
Systematic review
Terminology
Thy terminology
Thyroid
Thyroid gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The UK Royal College of Pathologists (RCPath) Thy terminology is an internationally recognised system for reporting thyroid fine needle aspiration. The terminology has been used throughout the UK and Ireland, in some parts of Italy and Switzerland, and elsewhere in the world. There is no systematic review of the literature specifically addressing the use of the non‐diagnostic for cytological diagnosis‐Thy1/Thy 1c category in the UK RCPath terminology. Methods A comprehensive literature search of online databases was conducted in October 2019 specifically examining overall reported rates of Thy1 and Thy1c in aspirates classified according to the UK Thy terminology. Results Twenty‐five articles were identified showing a Thy1 rate of 13.4% (2540/18 920). The studies were then stratified according to whether or not the patients underwent rapid on‐site evaluation (ROSE): 6.0% (353/5841; range 3.0%‐10.9%) of ROSE aspirates were Thy1 whereas 18.5% (2072/11 204; range 7.9%‐43.3%) of non‐ROSE patients were Thy1; (P 
ISSN:0956-5507
1365-2303
DOI:10.1111/cyt.12804